Disease Domain | Count |
---|---|
Infectious Diseases | 9 |
Neoplasms | 5 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 9 |
Therapeutic vaccine | 3 |
Genetically engineered subunit vaccine | 3 |
Small molecule drug | 1 |
Multivalent vaccine | 1 |
Top 5 Target | Count |
---|---|
PD-1(Programmed cell death protein 1) | 1 |
M.tb bc1(mycobacterial cytochrome bc1) | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date16 Dec 2024 |
Sponsor / Collaborator |
Start Date09 Dec 2024 |
Sponsor / Collaborator |
Start Date13 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant Zoster vaccine (Maxhealth) | Herpes Zoster More | Phase 3 |
Recombinant Trivalent Subunit Rotavirus Vaccine(Maxhealth) | Viral gastroenteritis due to Rotavirus More | Phase 2 |
Respiratory Syncytial Virus Vaccine (maxvax) | Respiratory Syncytial Virus Infections More | Phase 1/2 |
AYK103 | Liver Cancer More | Early Phase 1 |
MKK-RHP12 | Metapneumovirus infection More | Preclinical |